written by reader JEFF BROWN RECENT TEASER

By alas, April 27, 2020

FOR EXPONENTIAL TECH, regarding a small biotech:
”In July 2018, this biotech announced positive results for its Phase 1 clinical trials. And get this. This drug has been used for many years in Japan with few adverse side effects.
Because of this, the FDA granted the drug a qualified infectious disease product designation. In other words, the FDA allowed the company to skip Phase 2 trials and move directly into Phase 3.”
”It’s 2020… and antibacterial infections are killing people at a rate similar to the Middle Ages.
Yet we’re using antibiotics made in the 1980s to treat them. These antibiotics are terribly ineffective today. Even dangerous to rely on.
The CDC warns that 2.8 million Americans will be affected just this year.
It’s why the FDA fast-tracked the approval of the most powerful antibiotic in nearly 40 years.”

Any idea what company this is?

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

14 Comments
Inline Feedbacks
View all comments
btjossem
Irregular
btjossem
April 27, 2020 11:45 am

I have been researching this and haven’t gotten terribly far, but thought I would throw this 1 out.
https://www.marketbeat.com/stocks/NASDAQ/SPRO/
Spero therapeutics
I got here because it was listed as a company that Google has invested in.
That was mentioned in Jeff Brown’s audio (that I finally had to stop listening to… LONG, AS USUAL)
the current market Cap: $204 million
I think Jeff indicated it was $180 million
pretty close.
It’s up about 18% today, 4/27.
I still haven’t determined if they have a drug that has skipped phase 2.

👍 75
David
Guest
David
April 27, 2020 12:04 pm
Reply to  btjossem

Spero (SPRO) does have a pipeline that is focused on multi-drug resistant (MDR) pathogens. They have several trials in progress and recently received orphan drug status for SPR720 which treats nontuberculous myobacterial infections.

They also just appointed Scott Jackson to BoD. He was CEO of Celator Pharm. until it was acquired by Jazz Pharma.

samwiebaux
Member
samwiebaux
April 27, 2020 1:19 pm

TRAVIS, WHAT ABOUT JEFF HOWARD’S BIOTECH, STAGE 3, OUT OF MASSACHUSETTS – ANY IDEA WHAT IT IS???

👍 65
samwiebaux
Member
samwiebaux
April 27, 2020 1:27 pm

I just posted this. (Spero Therapeutics, us military, antibiotic trials) Came up with SPERO ! I BELIEVE THIS MAY BE IT! ABOUT $10

David
Guest
David
April 27, 2020 3:53 pm
Reply to  samwiebaux

SPRO is up about 20% today. Institutional ownership is ~48%. No insider trades reported since 2018. Insiders own ~18%. This has definitely been a pump today. It will be curious to see if they follow with an offering.

Dave
Member
Dave
April 27, 2020 10:05 pm
Reply to  David

what kind of offering do you suspect?

David
Guest
David
April 27, 2020 11:07 pm
Reply to  Dave

I was doing some reading earlier. They just closed an offering in Feb. that raised $30M on 1M shares. So I don’t see a new offering so close in timing. They do have a trial in Phase 3 which is due to report in Q3 2020. They also recently received $15M from BARDA for reimbursements due to a milestone achievement. GlaxoSmithKline is an “insider” by virtue of shares held. All of these factors are in line with Jeff Brown’s mystery bio-tech.

dougly
Irregular
dougly
May 10, 2020 1:35 am
Reply to  alas

I’ve been following this discussion. I felt strongly that the dots lined up on SPRO (Spero). Bought it at $12. However, for such an exciting story the stock has been fumbling around – a bit of a gain, a bit of a loss. Really nothing special so far. I think there’s an announcement in July. Hope they have a catalyst to pull them up and out. So far, not much to write home about.

👍 77
btjossem
Irregular
btjossem
May 10, 2020 10:02 am
Reply to  dougly

I had sideline money back when I looked at this and purchased for $10.31. It jumped up initially and has remained around the $12 mark ($11.78 as of Friday, 5/8). July 1 was mentioned as potential news, but it’s really Q3 the target for the study news. That said, it may be September. I’m going to be patient, but I’m not certain how patient. It’s 52 week high is a mere $14.38. If it were to move to $13 or above, I will be inclined to “count my lucky stars” and take a fortunate gain and go elsewhere.

DOESurv
Guest
DOESurv
April 29, 2020 8:45 am

So, its Spero but should be Iterum (ITRM) who will be first to market with an oral penem.

btjossem
Irregular
btjossem
April 29, 2020 2:17 pm
Reply to  DOESurv

That may be the case that they will be “1st to market with oral Pentm”, but I don’t see how ITRM can fit into Jeff Brown’s stock pick.
I see Leerink news from 2 different dates in the last year:
20190515 target cut to $16 from $18
20200124 target cut to $2 from $4
If one considers they have approximately 14.4 million shares and you multiply that times $8.25 (52 week high)
(may have hit 52 week high sometime in May, 2019)
52 week High Market Cap = $118 million (doesn’t get close to $180 million)
they may be 1st to the punch, and if Jeff Brown is targeting ITRM, then I would think that his data presented is very misleading… Okay, INCORRECT!

DOESurv
Guest
DOESurv
April 30, 2020 7:07 am
Reply to  btjossem

Read my post – its Spero – but if he had a broader knowledge he’d know ITRM beats them to the punch and with more indications for the same class (oral penem). And at a cheaper price……

btjossem
Irregular
btjossem
April 30, 2020 12:28 pm
Reply to  DOESurv

I should have paid more attention to you yesterday and put on my risky thinking cap. I now see that ITRM is up today. I’ll have to do more research on these guys and see if they are worthy. Thanks for waking me up.